BR112017027528A2 - composição, painel, método para determinar a probabilidade de parto prematuro em uma fêmea grávida e método de detecção de ibp4 e shbg em uma fêmea grávida? - Google Patents

composição, painel, método para determinar a probabilidade de parto prematuro em uma fêmea grávida e método de detecção de ibp4 e shbg em uma fêmea grávida?

Info

Publication number
BR112017027528A2
BR112017027528A2 BR112017027528-7A BR112017027528A BR112017027528A2 BR 112017027528 A2 BR112017027528 A2 BR 112017027528A2 BR 112017027528 A BR112017027528 A BR 112017027528A BR 112017027528 A2 BR112017027528 A2 BR 112017027528A2
Authority
BR
Brazil
Prior art keywords
lyam1
ibp4
pregnant female
shbg
psg3
Prior art date
Application number
BR112017027528-7A
Other languages
English (en)
Inventor
Jay Boniface John
fleischer Tracey
Gassman Andrew
flick Jeff
bradford Chad
Polpitiya Ashoka
Edward Hickok Durlin
kearney Paul
Charles Critchfield Gregory
Original Assignee
Sera Prognostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sera Prognostics, Inc. filed Critical Sera Prognostics, Inc.
Publication of BR112017027528A2 publication Critical patent/BR112017027528A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4713Plasma globulins, lactoglobulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4745Insulin-like growth factor binding protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/368Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Abstract

a descrição fornece um par de biomarcadores isolados selecionados a partir do grupo que consiste em ibp4/shbg, ibp4/psg3, ibp4/lyam1, ibp4/igf2, clus/ibp3, clus/igf2, clus/lyam1, inhbc/psg3, inhbc/igf2, psg2/lyam1, psg2/igf2, psg2/lyam1, pedf/psg3, pedf/shbg, pedf/lyam1, cd14/lyam1 e apoc3/lyam1, em que o referido par de biomarcadores exibe uma alteração no valor de reversão entre fêmeas grávidas em risco de parto prematuro e controles de gestação. também é fornecido um método para determinar a probabilidade de parto prematuro em uma fêmea grávida compreendendo a medição em uma amostra biológica obtida da referida fêmea grávida de um valor de reversão para pelo menos um par de biomarcadores selecionados do grupo que consiste em ibp4/shbg, ibp4/psg3, ibp4/lyam1, ibp4/igf2, clus/ibp3, clus/igf2, clus/lyam1, inhbc/psg3, inhbc/igf2, psg2/lyam1, psg2/igf2, psg2/lyam1, pedf/psg3, pedf/shbg, pedf/lyam1, cd14/lyam1 e apoc3/lyam1 para determinar a probabilidade de parto prematuro na dita fêmea grávida.
BR112017027528-7A 2015-06-19 2016-06-17 composição, painel, método para determinar a probabilidade de parto prematuro em uma fêmea grávida e método de detecção de ibp4 e shbg em uma fêmea grávida? BR112017027528A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562182349P 2015-06-19 2015-06-19
US62/182,349 2015-06-19
US201562387420P 2015-12-24 2015-12-24
US62/387,420 2015-12-24
US201662290796P 2016-02-03 2016-02-03
US62/290,796 2016-02-03
PCT/US2016/038198 WO2016205723A2 (en) 2015-06-19 2016-06-17 Biomarker pairs for predicting preterm birth

Publications (1)

Publication Number Publication Date
BR112017027528A2 true BR112017027528A2 (pt) 2018-09-11

Family

ID=57546535

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027528-7A BR112017027528A2 (pt) 2015-06-19 2016-06-17 composição, painel, método para determinar a probabilidade de parto prematuro em uma fêmea grávida e método de detecção de ibp4 e shbg em uma fêmea grávida?

Country Status (14)

Country Link
US (3) US10392665B2 (pt)
EP (2) EP4321626A2 (pt)
JP (4) JP6840391B2 (pt)
KR (1) KR20180029046A (pt)
CN (2) CN115015552A (pt)
AU (2) AU2016279002B2 (pt)
BR (1) BR112017027528A2 (pt)
CA (1) CA2990000A1 (pt)
ES (1) ES2955883T3 (pt)
HK (1) HK1254669A1 (pt)
IL (1) IL256399B (pt)
PL (1) PL3311158T3 (pt)
RU (1) RU2724013C2 (pt)
WO (1) WO2016205723A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10928402B2 (en) 2012-12-28 2021-02-23 Nx Prenatal Inc. Treatment of spontaneous preterm birth
US20140287947A1 (en) * 2013-03-15 2014-09-25 Sera Prognostics, Inc. Biomarkers and methods for predicting preeclampsia
CN115015552A (zh) 2015-06-19 2022-09-06 赛拉预测公司 用于预测早产的生物标志物对
JP2019505815A (ja) 2015-12-04 2019-02-28 エヌエックス・プリネイタル・インコーポレイテッドNX Prenatal Inc. 自然早産リスクを層別化するための循環マイクロ粒子の使用
RU2019105691A (ru) * 2016-08-05 2020-09-08 Сера Прогностикс, Инк. Биомаркеры для прогнозирования преждевременных родов из-за преждевременного разрыва плодной оболочки при недоношенной беременности и идиопатических самопроизвольных родов
CA3032944A1 (en) * 2016-08-05 2018-02-08 Sera Prognostics, Inc. Biomarkers for predicting preterm birth in a pregnant female exposed to progestogens
WO2018071845A1 (en) * 2016-10-13 2018-04-19 Krishnamurti Tamar Priya A structured medical data classification system for monitoring and remediating treatment risks
JP2018140172A (ja) * 2017-02-28 2018-09-13 株式会社Nttドコモ データ収集装置及びデータ収集方法
CA3073192A1 (en) 2017-08-18 2019-02-21 Sera Prognostics, Inc Pregnancy clock proteins for predicting due date and time to birth
SG11202007319SA (en) * 2018-01-31 2020-08-28 Nx Prenatal Inc Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkers
JP2021512318A (ja) * 2018-01-31 2021-05-13 エヌエックス・プリネイタル・インコーポレイテッドNX Prenatal Inc. 自然早産のリスクを層別化するための循環マイクロ粒子の使用
WO2020201521A1 (en) * 2019-04-04 2020-10-08 Carmentix Pte. Ltd. Biomarker pairs of preterm birth
WO2020201520A1 (en) * 2019-04-04 2020-10-08 Carmentix Pte. Ltd. Biomarker pairs of preterm birth
EP3786977A1 (de) * 2019-08-29 2021-03-03 WPmed GbR Computerimplementiertes verfahren und elektronisches system zur prognose eines entbindungszeitpunkts
KR20220140727A (ko) * 2020-02-10 2022-10-18 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 비알코올성 지방간염 (nash) 바이오마커 및 이의 용도
WO2022034118A1 (en) 2020-08-11 2022-02-17 University College Cork - National University Of Ireland, Cork A method of predicting the risk of spontaneous pre-term birth (sptb)
CN112126683A (zh) * 2020-08-31 2020-12-25 中山大学 用于迟发型子痫前期诊断的标志物
US20230101470A1 (en) * 2020-10-27 2023-03-30 Lipocine Inc. Hydroxyprogesterone Caproate Compositions and Methods of Use in Preventing Preterm Birth
CN112730692B (zh) * 2021-01-08 2022-11-29 首都医科大学附属北京朝阳医院 用于预测胎膜早破的生物标记物和方法
CN112899360A (zh) * 2021-02-02 2021-06-04 北京航空航天大学 一种检测特雷彻·柯林斯综合征发生概率的组合物的应用方法
CN113223714B (zh) * 2021-05-11 2022-07-05 吉林大学 一种用于预测子痫前期风险的基因组合、子痫前期风险预测模型及其构建方法
WO2022246288A2 (en) * 2021-05-21 2022-11-24 Sera Prognostics, Inc. Biomarker pairs and triplets for predicting preterm birth
CN113933516A (zh) * 2021-09-06 2022-01-14 山东省妇幼保健院 早产潜在预测标志物筛选方法、早产检测试剂盒及其用途
WO2023110832A1 (en) 2021-12-13 2023-06-22 UNIVERSITé LAVAL Biomarkers for the prediction of preterm birth

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
DK0408295T3 (da) 1989-07-11 1996-09-16 Gen Probe Inc Fremgangsmåder til opformering af nukleinsyresekvenser
AU7674591A (en) 1990-04-12 1991-11-11 Adeza Biomedical Corporation Pregnancy induced hypertension and eclampsia immunoassay and reagents
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
EP0642667B1 (en) 1991-11-04 2001-01-10 Adeza Biomedical Corporation Screening method for identifying women at increased risk for preterm delivery
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US6678669B2 (en) 1996-02-09 2004-01-13 Adeza Biomedical Corporation Method for selecting medical and biochemical diagnostic tests using neural network-related applications
PL326750A1 (en) 1996-09-20 1998-10-26 Atherogenics Inc Method of diagnosing inflamatory diseases and mediators of such diseases
CA2418395C (en) 2000-08-09 2010-05-04 Maruho Co., Ltd. Protein induced by homogeneous blood transfusion and dna encoding the same
GB0026823D0 (en) 2000-11-02 2000-12-20 King S College London Diagnosis of pre-eclampsia
CA2439854A1 (en) 2001-03-01 2002-09-12 Epigenomics Ag Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
WO2002088750A2 (en) 2001-05-02 2002-11-07 Oxford Glycosciences (Uk) Ltd Proteins, genes and their use for diagnosis and treatment of breast cancer
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
KR20110019357A (ko) 2002-08-06 2011-02-25 더 존스 홉킨스 유니버시티 난소암의 검출을 위한 생물 마커의 용도
AU2003290775A1 (en) 2002-11-14 2004-06-03 Ciphergen Biosystems, Inc. Biomarkers for intra-amniotic inflammation
US7541182B2 (en) 2003-02-13 2009-06-02 Yale University In vitro test to detect risk of preeclampsia
US8068990B2 (en) 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
JP2008500952A (ja) 2003-07-15 2008-01-17 ジェノバ・リミテッド 心臓血管障害で減少する分泌ポリペプチド種
WO2005017192A2 (en) 2003-08-14 2005-02-24 The General Hospital Corporation Screening for gestational disorders
US20050043640A1 (en) 2003-08-21 2005-02-24 Chang Alexander C. Remote electrocardiogram for early detection of coronary heart disease
US7344892B2 (en) * 2003-09-23 2008-03-18 Beth Israel Deaconess Medical Center, Inc. Screening for gestational disorders
US20050233400A1 (en) 2004-03-03 2005-10-20 Weiner Carl P Proteomic method for predicting success of rescue cerclage
US7700573B2 (en) 2004-03-23 2010-04-20 Oncotherapy Science, Inc. Method for diagnosing non-small lung cancer
EP1975242B1 (en) 2004-08-27 2011-03-02 Gen-Probe Incorporated Single-primer nucleic acid amplification methods
US20080090759A1 (en) * 2004-08-30 2008-04-17 Robert Kokenyesi Methods and kits for predicting risk for preterm labor
WO2006029838A2 (en) 2004-09-14 2006-03-23 Geneprot Inc. Secreted polypeptide species involved in alzheimer’s disease
CA2591926A1 (en) 2004-09-20 2006-03-30 Proteogenix, Inc. Diagnosis of fetal aneuploidy
EP1836496A2 (en) 2004-11-08 2007-09-26 Nanobac Life Sciences Methods and compositions for protein-hydroxy apatite complexes and their application in testing and modulating immunological system including a novel in vitro test for the detection of antibodies against calcium binding protein-hydroxy apatite complexes
CA2528531A1 (en) 2005-01-06 2006-07-06 Mount Sinai Hospital Markers of pre-term labor
US7811772B2 (en) 2005-01-06 2010-10-12 Eastern Virginia Medical School Apolipoprotein A-II isoform as a biomarker for prostate cancer
US7662570B2 (en) 2005-01-26 2010-02-16 The Trustees Of The University Of Pennsylvania Labor biomarkers, methods comprising same, and methods targeting same
KR101310000B1 (ko) 2005-03-11 2013-09-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘
WO2007022248A2 (en) 2005-08-16 2007-02-22 Sloan Kettering Institute For Cancer Research Methods of detection of cancer using peptide profiles
EP1929297B1 (en) 2005-09-29 2012-11-21 Caprion Proteomics USA, LLC Biomarkers for multiple sclerosis and methods of use thereof
EP1946121A2 (en) 2005-10-27 2008-07-23 Yale University, Inc. Urinary proteomic biomarker patterns in preeclampsia
US20070111326A1 (en) 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
EP1984743A4 (en) 2006-02-06 2010-02-10 Pacific Biotech Pty Ltd METHODS ASSOCIATED WITH GESTATION PERIODS
GB0605950D0 (en) 2006-03-24 2006-05-03 Jopejo Ltd Device for prediction of human or other mammalian labour onset
EP2924440A3 (en) 2006-06-07 2016-03-09 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
EP1914552A1 (en) 2006-10-20 2008-04-23 The University Of Newcastle Research Associates Limited Method for identifying women with an increased risk of pre-eclampsia
EP1914548A1 (en) 2006-10-20 2008-04-23 The University Of Newcastle Research Associates Limited Method for identifying women with an increased risk of preterm delivery
EP1914553A1 (en) 2006-10-20 2008-04-23 The University Of Newcastle Research Associates Limited Method for identifying women with an increased risk of foetal growth retardation
WO2008046160A1 (en) 2006-10-20 2008-04-24 Newcastle Innovation Limited Assay for the detection of biomarkers associated with pregnancy related conditions
US20100143949A1 (en) 2006-10-31 2010-06-10 George Mason Intellectual Properties, Inc. Biomarkers for colorectal cancer
EP2097094A4 (en) 2006-11-01 2011-01-05 George Mason Intellectual Prop BIOMARKERS FOR NEUROLOGICAL SUFFERING
WO2008079407A1 (en) 2006-12-26 2008-07-03 Brigham Young University Serum proteomics system and associated methods
WO2008085024A1 (en) 2007-01-12 2008-07-17 Erasmus University Medical Center Rotterdam Identification and detection of peptides relating to specific disorders
JP2010517525A (ja) 2007-02-01 2010-05-27 ダイアグノスティク テクノロジーズ リミテッド 子癇前症リスクの判定方法
US20080233583A1 (en) 2007-02-20 2008-09-25 Regents Of The University Of California Biomarkers for preeclampsia
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
WO2008121340A1 (en) 2007-03-28 2008-10-09 Vermillion, Inc. Methods for diagnosing ovarian cancer
US20100113286A1 (en) 2007-05-05 2010-05-06 Gilles Andre Lajoie Methods for detection of preeclampsia
WO2008146100A1 (en) 2007-06-01 2008-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for absolute quantification of polypeptides
WO2009014987A2 (en) 2007-07-20 2009-01-29 The University Of Utah Research Foundation Identification and quantification of biomarkers for evaluating the risk of preterm birth
GB0724735D0 (en) 2007-12-19 2008-01-30 Psynova Neurotech Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
US20100017143A1 (en) 2008-01-30 2010-01-21 Proteogenix, Inc. Gestational age dependent proteomic changes of human maternal serum for monitoring maternal and fetal health
US20100016173A1 (en) 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2009108073A1 (en) * 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
KR20110005708A (ko) 2008-04-09 2011-01-18 더 유니버시티 오브 브리티시 콜롬비아 심장 동종이식 급성 거부반응 진단방법
US20110247404A1 (en) 2008-06-25 2011-10-13 University Of Utah Research Foundation Identifying and quantifying biomarkers associated with preeclampsia
US20110256560A1 (en) 2008-10-20 2011-10-20 University Health Network Methods and compositions for the detection of ovarian cancer
US20100216250A1 (en) 2009-02-20 2010-08-26 Lopez Mary Frances Methods for Predicting Trisomy 21 in a Fetus
US20120046261A1 (en) 2009-02-27 2012-02-23 University Of Utah Research Foundation Compositions and methods for diagnosing and preventing spontaneous preterm birth
EP2467716B1 (en) 2009-08-20 2015-01-28 University of Utah Research Foundation Identification and quantification of biomarkers for evaluating the risk of preterm birth
MX2012005015A (es) 2009-10-30 2012-06-12 Prometheus Lab Inc Metodos para diagnosticar sindrome de intestino irritable.
GB0922240D0 (en) 2009-12-21 2010-02-03 Cambridge Entpr Ltd Biomarkers
US20130040844A1 (en) 2010-01-28 2013-02-14 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers of aging for detection and treatment of disorders
TWI390204B (zh) 2010-02-11 2013-03-21 Univ Chang Gung Biomarker of bladder cancer and its detection method
EP2537025B1 (en) 2010-02-16 2016-04-27 Newcastle Innovation Limited Protein biomarkers for obstructive airways diseases
EP2601532B1 (en) 2010-08-06 2016-01-27 Mycartis N.V. Perlecan as a biomarker for renal dysfunction
CN102445534A (zh) * 2010-10-15 2012-05-09 无锡市凯奥善生物医药科技有限公司 一种孕妇早产及胎膜早破联检试剂盒
US20120190561A1 (en) 2010-11-15 2012-07-26 Ludwig Wildt Means and methods for diagnosing endometriosis
WO2012109592A1 (en) * 2011-02-11 2012-08-16 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
JP2014526032A (ja) * 2011-06-07 2014-10-02 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス.アー.エール.エル. 癌に対する循環バイオマーカー
RU2486519C1 (ru) * 2011-11-15 2013-06-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздравсоцразви Способ прогнозирования преждевременных родов и внутриутробного инфицирования плода
US20130130278A1 (en) * 2011-11-22 2013-05-23 Ottawa Hospital Research Institute Detection of risk for pregnancy-related medical conditions
WO2013081721A1 (en) 2011-11-30 2013-06-06 Battelle Memorial Institute Biomarkers for lymphoma
US9797903B2 (en) 2012-10-24 2017-10-24 Winthrop-University Hospital Non-invasive biomarker to identify subject at risk of preterm delivery
US10279018B2 (en) 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
US20160003837A1 (en) 2013-01-08 2016-01-07 Duke University Biomarkers for the prediction of preterm birth
US20140287948A1 (en) 2013-03-15 2014-09-25 Sera Prognostics, Inc. Biomarkers and methods for predicting preterm birth
CA2907120C (en) 2013-03-15 2023-10-17 Sera Prognostics, Inc. Biomarkers and methods for predicting preterm birth
US20140287947A1 (en) 2013-03-15 2014-09-25 Sera Prognostics, Inc. Biomarkers and methods for predicting preeclampsia
CN115015552A (zh) 2015-06-19 2022-09-06 赛拉预测公司 用于预测早产的生物标志物对
RU2019105691A (ru) 2016-08-05 2020-09-08 Сера Прогностикс, Инк. Биомаркеры для прогнозирования преждевременных родов из-за преждевременного разрыва плодной оболочки при недоношенной беременности и идиопатических самопроизвольных родов
CA3032944A1 (en) 2016-08-05 2018-02-08 Sera Prognostics, Inc. Biomarkers for predicting preterm birth in a pregnant female exposed to progestogens
CA3073192A1 (en) 2017-08-18 2019-02-21 Sera Prognostics, Inc Pregnancy clock proteins for predicting due date and time to birth

Also Published As

Publication number Publication date
EP3311158A4 (en) 2019-01-23
HK1254669A1 (zh) 2019-07-26
KR20180029046A (ko) 2018-03-19
JP6840391B2 (ja) 2021-03-10
ES2955883T3 (es) 2023-12-07
US10961584B2 (en) 2021-03-30
AU2022241477A1 (en) 2022-10-20
JP2018524581A (ja) 2018-08-30
AU2016279002B2 (en) 2022-06-30
RU2017144232A3 (pt) 2019-12-24
US10392665B2 (en) 2019-08-27
EP3311158B1 (en) 2023-08-30
CN108450003B (zh) 2022-04-01
US20210180135A1 (en) 2021-06-17
EP3311158C0 (en) 2023-08-30
JP2020165993A (ja) 2020-10-08
PL3311158T3 (pl) 2023-11-27
CN115015552A (zh) 2022-09-06
RU2724013C2 (ru) 2020-06-18
JP2022145783A (ja) 2022-10-04
JP7385951B2 (ja) 2023-11-24
US20170022565A1 (en) 2017-01-26
CN108450003A (zh) 2018-08-24
JP2022173239A (ja) 2022-11-18
IL256399A (en) 2018-02-28
IL256399B (en) 2022-09-01
WO2016205723A3 (en) 2017-02-16
AU2016279002A1 (en) 2018-01-25
EP4321626A2 (en) 2024-02-14
EP3311158A2 (en) 2018-04-25
US20200071761A1 (en) 2020-03-05
RU2017144232A (ru) 2019-07-19
CA2990000A1 (en) 2016-12-22
WO2016205723A2 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
BR112017027528A2 (pt) composição, painel, método para determinar a probabilidade de parto prematuro em uma fêmea grávida e método de detecção de ibp4 e shbg em uma fêmea grávida?
CY1118864T1 (el) Μεθοδοι και συνθεσεις για μη επεμβατικη προγεννητικη διαγνωση εμβρυϊκων ανευπλοειδιων
BR112017023478A2 (pt) Melhoramento do efeito das células t car- concebidas por meio de vacinação de ácido nucleico
WO2016138105A3 (en) Assays to determine dna methylation and dna methylation markers of cancer
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
MX2008013454A (es) Metodos y equipos para la prediccion de riesgo en partos prematuros.
ES2721051T3 (es) Método para la evaluación no invasiva de variaciones genéticas
BR112016007106A2 (pt) dispositivo e método de teste de gravidez melhorado
BR112014026661A2 (pt) método in vitro para diagnóstico e vigilância do câncer
WO2010060102A3 (en) Prediction and prevention of preeclampsia
BR112014006432A2 (pt) biomarcadores do câncer de pulmão e seus usos
EP3495502A3 (en) Biomarkers for premature birth
EA201591582A1 (ru) Анализ транскриптома материнской плазмы с применением массивного параллельного секвенирования рнк
EP4324937A3 (en) Detecting hematological disorders using cell-free dna in blood
CL2018001343A1 (es) Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson
EA201591682A1 (ru) Пренатальный скрининг
WO2013112836A3 (en) Diagnostic and prognostic biomarkers for cancer
Huppertz Maternal and fetal factors and placentation: implications for pre-eclampsia
BR112015027249A2 (pt) método de diagnóstico de câncer
CO2019009796A2 (es) Composición para la medición, prevención o alivio del envejecimiento de la piel usando hapln1
BR112018075223A2 (pt) assinaturas de biomarcador de lúpus eritematoso sistêmico e usos das mesmas
WO2015173430A3 (en) Early placenta insulin-like peptide (pro-epil)
BR112014017952A8 (pt) Processo para prognosticar in vitro em uma amostra sanguínea a probabilidade para um paciente evoluir para uma dengue severa
WO2013119279A3 (en) Assays and methods for the diagnosis of ovarian cancer
BR112018001157A2 (pt) profilaxia da hipertensão e doenças cardiovasculares

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]